Novartis Q2 surpasses estimates despite 50% Entresto sales drop

Novartis reported Q2 core operating profit that beat market expectations, helped by lower-than-expected costs. This supported results despite a sharp decline in sales of its top-selling heart failure drug Entresto. The mix suggests improved near-term earnings resilience, with the cost offset mitigating demand weakness.